Synovial Sarcoma

Slide 1 · Synovial Sarcoma

A translocation-associated malignant soft tissue tumor with variable epithelial differentiation

Robbins-based pathology lecture | suitable for advanced undergraduate and pathology training

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Define

Explain why the disease name does not establish synovial origin

Genetics

Interpret SS18::SSX fusion as a diagnostic and oncogenic event

Morphology

Discriminate monophasic and biphasic patterns

Diagnosis

Integrate morphology, immunohistochemistry, and molecular assays

Clinical

Relate extent, age, and metastatic pattern to outcomes

Slide 3 · What makes synovial sarcoma distinct?

A sarcoma that may express epithelial markers despite arising in soft tissue

Characteristic SS18::SSX fusion

Monophasic or biphasic morphology

Slide 4 · The term “synovial” is historical

Historical assumption

Early cases near the knee suggested a synovial origin

Anatomic proximity drove the original name

Current interpretation

Tumors may arise where synovium is absent

Epithelial differentiation does not establish synovial derivation

Slide 5 · Position within soft tissue pathology

Soft tissue mass

Determine benign versus malignant features

Establish lineage or molecular subtype

Classify the sarcoma

Synovial sarcoma is a molecularly defined soft tissue sarcoma.

Slide 6 · Who develops synovial sarcoma?

Typically affects adolescents and young adults

Approximately 10% of soft tissue sarcomas

Age helps define a clinical prior probability, not a diagnosis

Occurrence outside the usual age range does not exclude it

Slide 7 · Usual anatomical presentation

Often a deep soft tissue mass of an extremity

The thigh and leg are representative sites in the Robbins soft tissue table

Joint-adjacent tumors are possible but not required

Absence of synovial tissue is compatible with the diagnosis

Slide 8 · A deceptively indolent history

A slowly recognized, persistent deep soft tissue mass may still be malignant

Masses may have been present for several years

Duration alone is not a reliable benign-versus-malignant discriminator

Slide 9 · Clinical impression versus biological identity

Clinical impression

Slowly enlarging mass in a young individual

May initially resemble a less aggressive soft tissue lesion

Biological identity

Malignant, fusion-associated mesenchymal neoplasm

Can metastasize despite an extended prediagnostic history

Slide 10 · Four anchors for recognition

Patient

Adolescent or young adult is typical

Site

Deep soft tissue, commonly in an extremity

Microscopy

Uniform spindle cells ± epithelial gland-like structures

Molecular

SS18::SSX rearrangement is the defining genetic hallmark

Slide 11 · Simple fusion-driven versus complex-karyotype sarcomas

Synovial sarcoma

Recurrent t(X;18) creates SS18::SSX

Characteristic genetic event provides diagnostic leverage

Undifferentiated pleomorphic sarcoma

Typically complex and heterogeneous karyotype

Lacks a diagnostic lineage or specific rearrangement by definition

Slide 12 · The defining t(X;18) event

Chromosome X

Chromosome 18

SSX1 / SSX2 / SSX4

SS18

SS18::SSX

T(X;18)(p11;q11): Reciprocal chromosomal rearrangement

Slide 13 · Fusion nomenclature matters

The modern convention is SS18::SSX

Common partners include SSX1 and SSX2; SSX4 is less frequent

The shorthand t(X;18)(p11;q11) describes the chromosomal exchange

Fusion protein, fusion transcript, and a break-apart signal are related but distinct assay targets

Slide 14 · How a chromosomal fusion becomes oncogenic

T(X;18) juxtaposes genes

SS18::SSX fusion transcript

Chimeric nuclear protein

Disordered transcriptional program

This is a mechanistic conceptual chain, not a quantitative signaling pathway.

Slide 15 · Chromatin remodeling is the molecular target

The fusion protein interferes with normal chromatin remodeling

Dysregulated chromatin regulation changes gene expression

Altered transcriptional programs contribute to oncogenic cell behavior

Robbins does not assign a single linear downstream pathway

Slide 16 · From fusion to tumor phenotype

Altered chromatin-regulatory machinery

Aberrant gene expression

Disrupted differentiation program

Malignant mesenchymal growth

Schematic causal model: Distal molecular details are simplified.

Slide 17 · A fusion can be diagnostically specific

The value of SS18::SSX lies in identifying a particular tumor entity

Anatomic site and histology alone are less specific

Molecular testing adjudicates many ambiguous spindle-cell tumors

Slide 18 · Fusion as driver and biomarker

Biological role

Oncogenic protein perturbs chromatin regulation

Mechanistic role: Altered transcriptional control

Diagnostic role

Specific genetic signature can confirm identity

Marker role: Differentiates from morphologic mimics

Slide 19 · Do not confuse biomarker functions

Diagnostic

SS18::SSX establishes tumor identity in an appropriate context

Prognostic

Stage, tumor extent, and age correlate with outcome

Predictive

MAGE-A4 and certain HLA types determine eligibility for a specific engineered T-cell therapy

Unproven

Do not assume SSX fusion partner alone dictates clinical benefit

Slide 20 · Histologic heterogeneity is central

One disease can produce different architectural patterns

Monophasic: Tightly packed spindle cells

Biphasic: Spindle cells plus epithelial gland-like structures

Slide 21 · Monophasic pattern: Architecture

Uniform spindle cells in compact fascicles

Schematic — original editable illustration; Not a histologic specimen

Slide 22 · Monophasic tumor: Constituent cells

Relatively uniform spindle-shaped tumor cells

Scant cytoplasm

Dense chromatin

Short fascicles create an extremely cellular appearance

Slide 23 · Why the monophasic pattern is challenging

A spindle-cell architecture is not exclusive to synovial sarcoma

Uniformity can resemble other mesenchymal neoplasms

The epithelial component may be inconspicuous or absent in a sampled section

Molecular specificity becomes important when morphology overlaps

Slide 24 · Monophasic does not mean molecularly different

A purely spindle-cell appearance can still carry SS18::SSX

Morphology describes differentiation patterns

Molecular analysis identifies the disease-defining genetic event

Slide 25 · Biphasic pattern: Two components

Uniform spindle cells in compact fascicles

Gland-like epithelial structures

Schematic — original editable illustration; Not a histologic specimen

Slide 26 · Biphasic tumor: The epithelial element

Gland-like structures accompany the spindle-cell component

Epithelioid cells range from cuboidal to columnar

These structures constitute epithelial differentiation within a sarcoma

The epithelial element makes keratin expression biologically plausible

Slide 27 · Monophasic versus biphasic pattern

Monophasic

Uniform spindle cells with scant cytoplasm

Dense chromatin; Short, tightly packed fascicles

Biphasic

Similar spindle component PLUS epithelioid cells

Cuboidal-to-columnar cells forming gland-like structures

Slide 28 · Epithelial features are not the same as carcinoma

Synovial sarcoma can form gland-like structures and express keratins

A malignant soft tissue tumor can display divergent differentiation

Location, morphology, and SS18::SSX clarify the lineage

Slide 29 · Poorly differentiated morphology: Supplemental context

NCI describes a poorly differentiated morphologic category

Such tumors can resemble other high-grade round-cell or spindle-cell malignancies

Reduced morphologic specificity increases dependence on immunophenotypic and molecular testing

Do not infer exact genotype or prognosis from a small biopsy alone

Slide 30 · Microscopic reporting checklist

Cell form

Spindle, epithelioid/glandular, or less differentiated

Architecture

Fascicular versus biphasic gland-forming areas

Cytology

Cellular uniformity, nuclear features, atypia

Sampling

Document component distribution and biopsy limitations

Ancillary tests

Record stains and fusion-directed results

Slide 31 · What a biopsy can show—and miss

What may be present

Uniform spindle-cell fascicles

Focal keratin / EMA expression

A fusion-directed diagnostic signal

What may be missed

Gland-like component in limited tissue

Heterogeneity across the primary lesion

Features needed for comprehensive resection assessment

Slide 32 · The most informative morphologic question

Is there convincing spindle-to-epithelial differentiation within the same malignancy?

If yes: Biphasic synovial sarcoma enters the differential

If no: Monophasic synovial sarcoma remains plausible

Slide 33 · Diagnostic reasoning in a spindle-cell mass

Clinicoradiologic context

H&E architecture and cellular details

Broad but focused immunohistochemistry

Fusion-directed confirmation

This is a teaching algorithm; Actual panels depend on morphology and site.

Slide 34 · Major diagnostic confounders

MPNST

Can resemble a cellular spindle-cell sarcoma

Solitary fibrous tumor

May display monotonous spindle morphology

Other spindle-cell sarcomas

Overlap in fascicular architecture

Sarcomatoid carcinoma

Can express epithelial markers

Rhabdomyosarcoma

Muscle-specific differentiation separates the entity

Slide 35 · Monophasic synovial sarcoma versus MPNST

Synovial sarcoma

Often relatively uniform spindle cell nuclei

Keratins/EMA may be detectable; SS18::SSX is decisive

MPNST

May show wavy or buckled spindle nuclei

S100/SOX10 and H3K27me3 loss are context-dependent clues

Slide 36 · Synovial sarcoma versus solitary fibrous tumor

Synovial sarcoma

Tight fascicles, variable epithelioid differentiation

SS18::SSX drives diagnosis

Solitary fibrous tumor

Characteristic ectatic branching vasculature table

STAT6 nuclear staining / NAB2::STAT6 support SFT

Slide 37 · Synovial sarcoma versus sarcomatoid carcinoma

Synovial sarcoma

May show keratin-positive spindled cells

Deep tissue mass; SS18::SSX supports sarcoma identity

Sarcomatoid carcinoma

May also be spindle shaped and keratin positive

Look for epithelial primary or in situ component; Distinct molecular context

Slide 38 · Synovial sarcoma versus rhabdomyosarcoma

Synovial sarcoma

SS18::SSX; Variable epithelial differentiation

Morphology ranges from spindled to biphasic

Rhabdomyosarcoma

True skeletal muscle differentiation

Myogenin and other myogenic regulators support lineage

Slide 39 · Keratins: An unusual clue in a sarcoma

Epithelial antigens may be positive in synovial sarcoma

Keratins, particularly with biphasic morphology

A positive keratin stain is supportive—not independently diagnostic

Slide 40 · Epithelial membrane antigen complements keratins

EMA and cytokeratins support epithelial differentiation

Staining may be focal, especially in monophasic tumors

Lack of diffuse staining does not exclude the diagnosis

Marker panels must be interpreted against H&E and fusion studies

Slide 41 · TLE1 is supportive, not specific

TLE1 nuclear expression is frequent but occurs in mimics

A TLE1-positive spindle-cell lesion is not automatically synovial sarcoma

Prioritize lineage exclusion and fusion-directed confirmation

Slide 42 · Fusion-specific SS18::SSX immunohistochemistry

Detects a fusion-associated nuclear epitope

Provides strong evidence of synovial sarcoma when validated staining is positive

A negative result may be technical or reflect epitope variants

Discordant cases merit molecular testing; Sensitivity is not absolute

Slide 43 · Fusion-specific antibody versus TLE1

SS18::SSX fusion-specific IHC

Targets a fusion-dependent neoepitope

Generally high specificity; False negatives are possible

TLE1 nuclear IHC

Reflects a frequently expressed regulatory protein

Good screening context, but not sufficiently specific alone

Slide 44 · Ancillary techniques answer different questions

Keratins / EMA

Is epithelial differentiation detectable?

TLE1

Is there a supportive, nonspecific phenotype?

SS18::SSX IHC

Is the characteristic fusion neoepitope present?

SS18 break-apart FISH

Is SS18 rearranged?

RNA-based fusion testing

Which specific fusion transcript is present?

Slide 45 · A break-apart FISH assay is not fusion sequencing

SS18 split signals indicate rearrangement at the locus

They do not, by themselves, specify the partner transcript

A positive assay supports the diagnosis when morphology is compatible

Slide 46 · Where RNA-based fusion testing adds value

Equivocal morphology

Nondiagnostic immunophenotype

Fusion partner / transcript identification

Integrated molecular diagnosis

Interpret negative testing in light of RNA quality, assay coverage, and tumor fraction.

Slide 47 · Positive and negative fusion-directed results

Positive result

Interpreted with a compatible tumor context

Usually resolves a broad spindle-cell differential

Negative or discordant result

Re-examine controls, specimen quality and test coverage

Consider additional IHC, FISH or sequencing before exclusion

Slide 48 · Integrated diagnostic hierarchy

Morphology suggests synovial sarcoma

Keratins / EMA ± TLE1 support lineage

SS18::SSX IHC or SS18 molecular analysis

Integrated diagnosis

A single nonspecific positive stain never establishes the diagnosis.

Slide 49 · Three avoidable diagnostic shortcuts

Do not infer synovial origin from the tumor name

Do not identify a sarcoma solely by keratin or TLE1 positivity

Do not dismiss a case solely because glands are absent

Do not treat a negative single fusion-directed assay as infallible

Slide 50 · The signed-out diagnosis is an integration

Morphologic pattern + differential exclusions + validated molecular evidence

Ancillary assays confirm a biologic entity; They do not replace morphology and clinical context

Record uncertainty rather than force a lineage label

Slide 51 · Recognized metastatic destinations

Primary soft tissue mass

Lung metastasis

Regional nodal metastasis

Two potential routes from the primary tumor (not a sequential cascade)

Slide 52 · Regional nodal spread deserves attention

Regional lymph nodes as a metastatic site

Nodal involvement is unusual for sarcomas in general

The possibility affects clinical staging and assessment

Slide 53 · What drives clinical risk?

Tumor stage

Extent and dissemination are central prognostic variables

Patient age

Age with survival variation

Tumor size

Larger tumors are less favorable in NCI pediatric data

Local invasiveness

Important in pediatric risk descriptions

Site

Proximal or nonextremity presentations may alter outcome

Slide 54 · Interpreting published survival ranges

Robbins gives 62%–83% five-year disease-specific survival

This is a textbook-reported range, not a single modern pooled estimate

Stage and age contribute to variability; Cohort definition matters

Slide 55 · Localized and disseminated disease are different clinical problems

Localized disease

Aim for durable local control and prevention of spread

Surgery is central; Adjunctive treatment is risk-adapted

Metastatic disease

Systemic management and selective local measures

Biomarkers can determine eligibility for specialized treatment

Slide 56 · Multidisciplinary assessment is essential

Sarcoma-experienced pathology integrates tissue and fusion testing

Imaging defines lesion extent and resectability

Surgery, medical oncology, and radiation oncology consider local and systemic risk

Do not plan treatment solely from a small-biopsy morphology label

Slide 57 · Local treatment is typically limb sparing

Limb-sparing surgery

Achieving appropriate local control requires anatomic planning

Radiotherapy may be part of individualized management rather than an automatic rule

Slide 58 · Chemotherapy: Textbook statement and practice nuance

Robbins overview

Mentions chemotherapy alongside limb-sparing surgery

This is not a universal instruction for every localized tumor

Risk-adapted practice

Use depends on disease extent, age, resectability and protocols

NCI pediatric guidance explicitly stratifies low-risk surgery-only patients

Slide 59 · Treatment biomarkers: An important distinction

SS18::SSX

Disease-defining diagnostic rearrangement

MAGE-A4

Tumor antigen relevant to a specific engineered TCR-T therapy

HLA-A*02 variants

Host antigen-presentation eligibility for that therapy

Stage / resectability

Clinical variables defining the treatment setting

Slide 60 · MAGE-A4-directed TCR-T therapy

Afamitresgene autoleucel: Autologous engineered T-cell receptor therapy

U.S. Indication includes patients aged 12 years or older with unresectable or metastatic disease after chemotherapy

Requires specified HLA-A*02 alleles AND MAGE-A4-positive tumor by an authorized companion diagnostic

Cytokine release syndrome is a potentially serious treatment toxicity

Slide 61 · Case 1: An indolent but deep mass

An otherwise healthy 22-year-old has a deep thigh mass present for two years. Biopsy shows uniform, tightly packed spindle cells and patchy keratin expression.

Question: Which molecular alteration would most strongly support synovial sarcoma?

Slide 62 · Case 1: Diagnostic resolution

Persistent deep extremity mass

Uniform spindle-cell fascicles

Epithelial-marker support

Demonstrate SS18::SSX

Extended symptom duration does not remove malignant potential.

Slide 63 · Case 2: Dual differentiation

A resection contains compact spindle-cell sheets and distinct gland-like structures lined by cuboidal cells. Both components belong to a single malignancy.

Question: What morphologic subtype is most consistent with these findings?

Slide 64 · Case 2: Biphasic synovial sarcoma

Two histologic components establish a biphasic pattern

Spindle + gland-forming epithelial differentiation

Use a fusion-directed test when needed to exclude mimics

Slide 65 · Case 3: An IHC pitfall

A spindle-cell tumor stains strongly for TLE1 but shows no convincing keratin staining. Fusion-specific immunostaining is negative on decalcified tissue.

Question: Is the diagnosis excluded, confirmed, or unresolved?

Slide 66 · Case 3: Handle discordant evidence

TLE1 alone is nonspecific

Verify sample quality and controls

Review lineage mimics and H&E

Use orthogonal molecular assay

Best classification may remain provisional until additional evidence is available.

Slide 67 · Consolidated exam-level distinctions

Historical name

No requirement for synovial origin

Signature

T(X;18) → SS18::SSX

Monophasic

Uniform spindle-cell fascicles

Biphasic

Spindle cells + epithelial gland-like structures

Metastases

Lungs and regional lymph nodes are recognized

Slide 68 · Final diagnostic safeguards

Morphology identifies a pattern; The fusion helps identify the entity

Keratins/EMA indicate differentiation, not an epithelial primary by themselves

TLE1 is supportive and not disease defining

Know the limits of every ancillary assay

Report subtype, molecular evidence and clinically consequential uncertainty

Slide 69 · Selected references and source boundaries

Primary textbook

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. Ch 26

Pediatric clinical detail

NCI Childhood Soft Tissue Sarcoma Treatment (PDQ), Synovial Sarcoma

IHC and molecular update

Molecular/pathology reviews and SS18::SSX antibody validation studies

Regulatory status

U.S. FDA TECELRA indication and updated prescribing letter